SV2010003513A - Sistema de administracion vaginal - Google Patents

Sistema de administracion vaginal

Info

Publication number
SV2010003513A
SV2010003513A SV2010003513A SV2010003513A SV2010003513A SV 2010003513 A SV2010003513 A SV 2010003513A SV 2010003513 A SV2010003513 A SV 2010003513A SV 2010003513 A SV2010003513 A SV 2010003513A SV 2010003513 A SV2010003513 A SV 2010003513A
Authority
SV
El Salvador
Prior art keywords
protection
drospirenone
membrane
administration system
strogen
Prior art date
Application number
SV2010003513A
Other languages
English (en)
Inventor
Christine Talling
Vladimir Hanes
Antti Keinaenen
Svante Holmberg
Hannu Nikander
Original Assignee
Bayer Schering Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40394262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2010003513(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07397042A external-priority patent/EP2062568A1/en
Priority claimed from EP07397043A external-priority patent/EP2062569B1/en
Application filed by Bayer Schering Pharma Oy filed Critical Bayer Schering Pharma Oy
Publication of SV2010003513A publication Critical patent/SV2010003513A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTA INVENCIÓN SE REFIERE A UN SISTEMA DE ADMINISTRACIÓN INTRAVAGINAL PARA LA LIBERACIÓN CONTROLADA DE DROSPIRENONA Y UN ESTRÓGENO Y, OPCIONALMENTE, TAMBIÉN COMPRENDE UNA O MAS SUSTANCIAS TERAPÉUTICAMENTE ACTIVAS O PROMOTORAS DE LAS SALUD CAPACES DE BRINDAR Y/O MEJORAR LA PROTECCIÓN CONTRA INFECCIONES BACTERIANA Y FÚNGICAS, Y/O MEJORAR LA PROTECCIÓN CONTRA ENFERMEDADES DE TRANSMISIÓN SEXUAL. EL SISTEMA DE ADMINISTRACIÓN COMPRENDE UNO O MAS COMPARTIMIENTOS, CADA UNO DE LOS CUALES COMPRENDE UN NÚCLEO Y UNA MEMBRANA QUE RECUBRE EL NÚCLEO, DICHO NÚCLEO Y DICHA MEMBRANA ESTÁN COMPUESTOS ESENCIALMENTE POR LA MISMA COMPOSICIÓN DE POLÍMERO O UNA COMPOSICIÓN DE POLÍMERO DIFERENTE, DONDE AL MENOS UN COMPARTIMIENTO COMPRENDE DROSPIRENONA Y AL MENOS UN COMPARTIMIENTO, QUE PUEDE SER IGUAL O DIFERENTE DEL QUE COMPRENDE DROSPIRENONA, COMPRENDE UN ESTRÓGENO, O UNA MEZCLA DE DROSPIRENONA Y UN ESTRÓGENO, Y DONDE LA MEMBRANA O LA SUPERFICIE DE LA MEMBRANA O AL MENOS UNO DE LOS NÚCLEOS COMPRENDE DICHA SUSTANCIA TERAPÉUTICAMENTE ACTIVA O PROMOTORA DE LA SALUD
SV2010003513A 2007-11-22 2010-03-22 Sistema de administracion vaginal SV2010003513A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07397042A EP2062568A1 (en) 2007-11-22 2007-11-22 Vaginal delivery system
EP07397043A EP2062569B1 (en) 2007-11-22 2007-11-22 Vaginal delivery system

Publications (1)

Publication Number Publication Date
SV2010003513A true SV2010003513A (es) 2010-08-09

Family

ID=40394262

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003513A SV2010003513A (es) 2007-11-22 2010-03-22 Sistema de administracion vaginal

Country Status (26)

Country Link
US (2) US20100285097A1 (es)
EP (1) EP2227220A1 (es)
JP (1) JP2011504484A (es)
KR (1) KR20100090708A (es)
CN (1) CN101873850A (es)
AR (1) AR069379A1 (es)
AU (1) AU2008327813A1 (es)
BR (1) BRPI0815936A2 (es)
CA (1) CA2705734A1 (es)
CL (1) CL2008003421A1 (es)
CO (1) CO6290642A2 (es)
CR (1) CR11493A (es)
DO (1) DOP2010000154A (es)
EA (1) EA018112B1 (es)
EC (1) ECSP10010104A (es)
IL (1) IL205588A0 (es)
MX (1) MX2010003656A (es)
NZ (1) NZ584216A (es)
PA (1) PA8805001A1 (es)
PE (1) PE20091025A1 (es)
SG (1) SG186002A1 (es)
SV (1) SV2010003513A (es)
TW (1) TW200927141A (es)
UY (1) UY31475A1 (es)
WO (1) WO2009066006A1 (es)
ZA (1) ZA201002122B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI121000B (fi) * 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginaalinen antojärjestelmä ja menetelmä sen valmistamiseksi
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8173750B2 (en) * 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
FI20095550A0 (fi) * 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
FI20095563A (fi) * 2009-05-20 2010-11-21 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
JP5813093B2 (ja) * 2010-03-28 2015-11-17 エベストラ・インコーポレイテッドＥｖｅｓｔｒａ，Ｉｎｃ． 膣内薬物送達デバイス
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EA201291298A1 (ru) * 2010-06-22 2013-09-30 Тева Вимен'С Хелс, Инк. Интравагинальные устройства, содержащие антихолинергические агенты, и способы их изготовления
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
BR112013011744B1 (pt) 2010-11-12 2021-04-27 The University Of Utah Research Foundation Dispositivo intravaginal para distribuição controlada de lubrificantes
SG190719A1 (en) * 2010-11-29 2013-07-31 Meiji Co Ltd Endometriosis prevention and/or improving agent, and food or drink composition containing same
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
KR101263916B1 (ko) 2011-01-11 2013-05-13 이장희 성 호르몬 방출 장치 및 이를 이용한 동물 피임 및 발정 유도 방법
AU2012268068B2 (en) 2011-06-06 2016-10-13 Auritec Pharmaceuticals Drug delivery device employing wicking release window
EP2731587A1 (en) * 2011-07-15 2014-05-21 Universiteit Gent Intravaginal delivery system
JP6170044B2 (ja) * 2011-07-20 2017-07-26 エフ． カイザー，パトリック 薬物送達のための膣内デバイス
CN104168902A (zh) 2011-08-26 2014-11-26 智利圣地亚哥大学 阴道内给药非类固醇抗炎药物美洛昔康和吡罗昔康用于中断女性排卵过程的用途
CN103007427B (zh) * 2011-09-21 2016-01-20 上海市计划生育科学研究所 缓控释宫内释药器及其制备方法
TWI615155B (zh) * 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
WO2013174735A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
EP2861215A4 (en) 2012-06-13 2015-04-22 Evofem Inc COMPOSITIONS AND METHODS FOR INCREASING THE EFFECTIVENESS OF RECIPROCAL MICROBICIDES
EP2890760A4 (en) 2012-08-30 2016-10-12 Atrp Solutions Inc DOUBLE MECHANISM THICKENERS FOR HYDRAULIC FRACKING FLUIDS
TR201808748T4 (tr) 2012-09-03 2018-07-23 Ecosea Farming S A Hidrobiyolojik türlerin kültürü ve/veya korunmasına yönelik rezervuar-kafes daldırma sistemi.
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014066480A1 (en) * 2012-10-23 2014-05-01 Estech Usa, Llc Treating conditions caused by abnormal growth of pathogens in body cavities
EP2951220B1 (en) 2013-02-04 2020-11-25 Pilot Polymer Technologies, Inc. Salt-tolerant star macromolecules
SE539540C2 (sv) * 2013-09-12 2017-10-10 Qpharma Ab Ett läkemedelsavgivningssystem för en eller flera aktiva beståndsdelar
KR20160083061A (ko) * 2013-11-05 2016-07-11 타리스 바이오메디컬 엘엘씨 삼투 약물 전달 디바이스들, 키트, 및 방법들
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US10413504B2 (en) * 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
KR102407408B1 (ko) 2013-12-19 2022-06-10 에보펨 인코포레이티드 알긴산계 항균성 화합물을 사용하는 염증 및 질병을 억제하기 위한 조성물 및 방법
WO2015153817A1 (en) * 2014-04-01 2015-10-08 Poly-Med, Inc. Contraceptive and related device
CA2956431C (en) 2014-07-03 2023-01-31 ATRP Solutions, Inc. Surfactant-compatible star macromolecules
US9884049B2 (en) 2014-07-14 2018-02-06 Orion Biotechnology Canada Ltd. Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof
CN104117135A (zh) * 2014-08-11 2014-10-29 崔仁海 阴道内植入式治疗装置
CN104558491A (zh) * 2014-12-25 2015-04-29 中南大学 能促进组织内膜生长的聚氨酯材料的制备方法
EP3294300A1 (en) * 2015-05-13 2018-03-21 Bayer Oy A long acting drug delivery device and its use in contraception
PE20211663A1 (es) * 2015-08-31 2021-08-26 Chr Hansen As Bacterias lactobacillus con actividad antifungica
BR112018012743A2 (pt) * 2015-12-21 2018-12-04 Bayer Oy método para fabricar um dispositivo de administração de medicamento e um dispositivo de administração de medicamento fabricado de acordo com o método
CN108472248A (zh) * 2015-12-21 2018-08-31 拜耳股份有限公司 制造阴道环的方法
CA3009697A1 (en) * 2016-01-04 2017-07-13 Jurox Pty Ltd Drug release device and use
KR101720145B1 (ko) * 2016-07-08 2017-04-07 (주)정가진면역연구소 여성 질염 예방 및 개선 기능성 조성물
CN110225750A (zh) 2016-10-04 2019-09-10 伊沃菲姆股份有限公司 细菌性阴道病的治疗和预防方法
PE20211195A1 (es) * 2017-09-27 2021-07-01 Bayer Oy Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica
WO2019210066A1 (en) * 2018-04-27 2019-10-31 Evestra, Inc. Estrogen prodrugs and methods of administering estrogen prodrugs
CN111989068A (zh) 2018-05-24 2020-11-24 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
JP2021524841A (ja) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
WO2020007780A1 (en) * 2018-07-02 2020-01-09 Artpred B.V. Method and kit for altering the outcome of an assisted reproductive technology procedure
KR102078462B1 (ko) * 2018-07-24 2020-02-17 주식회사 디네이쳐 질환경 개선 조성물 및 이를 포함하는 개선제
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption
CN110585246B (zh) * 2019-09-22 2020-06-02 深圳市多微生保健食品有限公司 一种阴道抑菌制剂及其制备方法
AU2020384227A1 (en) * 2019-11-12 2022-05-26 Poly-Med, Inc. Contraceptive medical devices
KR20210097421A (ko) * 2020-01-30 2021-08-09 주식회사 디네이쳐 펄스형 질내 약산성 환경 유지 조성물
IT202000029267A1 (it) * 2020-12-01 2022-06-01 Francesca FRIZZI Dispositivo vaginale
WO2023200974A1 (en) * 2022-04-14 2023-10-19 Yale University Nanoparticles and nanoparticle-releasing vaginal rings
WO2024030116A1 (en) * 2022-08-01 2024-02-08 Lupin Inc. Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48277A (en) * 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
DE3040978A1 (de) * 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4596576A (en) * 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
FR2618329B1 (fr) * 1987-07-22 1997-03-28 Dow Corning Sa Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US6544546B1 (en) * 1995-07-04 2003-04-08 Akzo Nobel, N.V. Ring-shaped devices
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1406634A1 (en) * 2001-07-13 2004-04-14 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
KR20040036928A (ko) * 2001-08-31 2004-05-03 쉐링 오와이 약물 전달 시스템
PT1429802E (pt) * 2001-09-28 2013-01-24 Tntgamble Inc Sistema de entrega para componente biológico
US20040247574A1 (en) * 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
EP1667619A4 (en) * 2003-09-19 2007-10-10 Drugtech Corp PHARMACEUTICAL FEEDING SYSTEM
CA2559224C (en) * 2004-03-24 2011-12-13 N.V. Organon Drug delivery system based on polyethylene vinylacetate copolymers
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
CA2614187A1 (en) * 2005-07-15 2007-01-25 Bayer Schering Pharma Aktiengesellschaft Drospirenone containing transdermal drug delivery devices and methods of delivery thereof

Also Published As

Publication number Publication date
CA2705734A1 (en) 2009-05-28
US20090142313A1 (en) 2009-06-04
KR20100090708A (ko) 2010-08-16
MX2010003656A (es) 2010-04-21
US20100285097A1 (en) 2010-11-11
JP2011504484A (ja) 2011-02-10
PE20091025A1 (es) 2009-08-17
CO6290642A2 (es) 2011-06-20
BRPI0815936A2 (pt) 2019-08-27
CR11493A (es) 2010-08-23
EA201070639A1 (ru) 2010-10-29
PA8805001A1 (es) 2009-06-23
EP2227220A1 (en) 2010-09-15
ECSP10010104A (es) 2010-06-29
WO2009066006A1 (en) 2009-05-28
CL2008003421A1 (es) 2009-08-07
AR069379A1 (es) 2010-01-20
NZ584216A (en) 2012-03-30
IL205588A0 (en) 2010-11-30
EA018112B1 (ru) 2013-05-30
ZA201002122B (en) 2011-06-29
AU2008327813A1 (en) 2009-05-28
UY31475A1 (es) 2009-07-17
DOP2010000154A (es) 2010-07-31
TW200927141A (en) 2009-07-01
SG186002A1 (en) 2012-12-28
CN101873850A (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
SV2010003513A (es) Sistema de administracion vaginal
CL2018001762A1 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas. (divisional solicitud 201402087).
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
GT200600297A (es) Nuevos anticuerpos anti-madcam
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
WO2010011609A3 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
AR087838A1 (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
PE20100057A1 (es) Sistema de suministro intrauterino para la liberacion controlada de progestageno
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
GT200500307A (es) Compuestos quimicos
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
AR113211A2 (es) Derivados de bencilfenilciclohexano y métodos de uso
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
GT201000160A (es) Derivados de aminobenzamida como agentes útiles para el control de parásitos de animales
CL2008000786A1 (es) Composicion farmaceutica proliposomal que comprende un concentrado de: un lipido formador de membranas con uno o mas fosfolipidos saturado o no saturado, un agente estabilizador de membrana seleccionado de un compuesto esterol y un vehiculo como un s
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
PE20141818A1 (es) Sistema para la administracion de farmacos